Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study

The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12‐ and 18‐month rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokota, Kenji, Uchi, Hiroshi, Uhara, Hisashi, Yoshikawa, Shusuke, Takenouchi, Tatsuya, Inozume, Takashi, Ozawa, Kentaro, Ihn, Hironobu, Fujisawa, Yasuhiro, Qureshi, Anila, de Pril, Veerle, Otsuka, Yasushi, Weber, Jeffrey, Yamazaki, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Concise Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916343/
https://www.ncbi.nlm.nih.gov/pubmed/31638282
http://dx.doi.org/10.1111/1346-8138.15103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916343/
https://www.ncbi.nlm.nih.gov/pubmed/31638282
http://dx.doi.org/10.1111/1346-8138.15103

Ejemplares similares